Summary of Study ST002550

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001642. The data can be accessed directly via it's Project DOI: 10.21228/M8FX54 This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST002550
Study TitleTargeted metabolomics for ARDS
Study SummaryAcute respiratory distress syndrome (ARDS) is a heterogeneous disease in its etiology and clinical aspects, and it has been an important interest in how to diagnose it and classify its subtypes, and apply them to treatment. Metabolomics is becoming important for identifying ARDS biology and distinguishing subtypes. The aim of this study is to identify metabolites distinguishing sepsis-induced ARDS patients from healthy controls using a targeted metabolomics approach, and to find out whether direct and indirect ARDS are metabolically distinct groups and confirm their metabolites and associated pathways. Targeted metabolomics was performed to explore metabolome changes between pARDS (pediatric ARDS) and eARDS.
Institute
Asan Medical Center
Last NameYoo
First NameHyun Ju
Address88, Olympic-ro 43-gil, Songpa-gu
Emailyoohyunju@amc.seoul.kr
Phone0230104029
Submit Date2023-03-30
Raw Data AvailableYes
Raw Data File Type(s)mzML
Analysis Type DetailLC-MS
Release Date2023-07-06
Release Version1
Hyun Ju Yoo Hyun Ju Yoo
https://dx.doi.org/10.21228/M8FX54
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:

Project:

Project ID:PR001642
Project DOI:doi: 10.21228/M8FX54
Project Title:Targeted metabolomics for ARDS
Project Summary:Acute respiratory distress syndrome (ARDS) is a heterogeneous disease in its etiology and clinical aspects, and it has been an important interest in how to diagnose it and classify its subtypes, and apply them to treatment. Metabolomics is becoming important for identifying ARDS biology and distinguishing subtypes. The aim of this study is to identify metabolites distinguishing sepsis-induced ARDS patients from healthy controls using a targeted metabolomics approach, and to find out whether direct and indirect ARDS are metabolically distinct groups and confirm their metabolites and associated pathways. Targeted metabolomics was performed to explore metabolome changes between pARDS (pediatric ARDS) and eARDS.
Institute:Asan Medical Center
Last Name:Yoo
First Name:Hyun Ju
Address:88, Olympic-ro 43-gil, Songpa-gu
Email:yoohyunju@amc.seoul.kr
Phone:0230104029

Subject:

Subject ID:SU002650
Subject Type:Human
Subject Species:Homo sapiens
Taxonomy ID:9606
Gender:Male and female

Factors:

Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id Factor
SA256087D_Serum_17Control
SA256088D_Serum_18Control
SA256089D_Serum_20Control
SA256090D_Serum_1Control
SA256091D_Serum_19Control
SA256092D_Serum_15Control
SA256093D_Serum_12Control
SA256094D_Serum_13Control
SA256095D_Serum_14Control
SA256096D_Serum_21Control
SA256097D_Serum_22Control
SA256098D_Serum_28Control
SA256099D_Serum_29Control
SA256100D_Serum_30Control
SA256101D_Serum_27Control
SA256102D_Serum_26Control
SA256103D_Serum_23Control
SA256104D_Serum_24Control
SA256105D_Serum_25Control
SA256106D_Serum_11Control
SA256107D_Serum_16Control
SA256108D_Serum_8Control
SA256109D_Serum_9Control
SA256110D_Serum_6Control
SA256111D_Serum_3Control
SA256112D_Serum_5Control
SA256113D_Serum_4Control
SA256114D_Serum_10Control
SA256115D_Serum_7Control
SA256116D_Serum_2Control
SA256117C_Serum_80eARDS
SA256118C_Serum_69eARDS
SA256119C_Serum_68eARDS
SA256120C_Serum_79eARDS
SA256121C_Serum_78eARDS
SA256122C_Serum_76eARDS
SA256123C_Serum_77eARDS
SA256124C_Serum_61eARDS
SA256125C_Serum_62eARDS
SA256126C_Serum_83eARDS
SA256127C_Serum_84eARDS
SA256128C_Serum_85eARDS
SA256129C_Serum_82eARDS
SA256130C_Serum_81eARDS
SA256131C_Serum_65eARDS
SA256132C_Serum_64eARDS
SA256133C_Serum_63eARDS
SA256134C_Serum_67eARDS
SA256135C_Serum_70eARDS
SA256136C_Serum_86eARDS
SA256137C_Serum_75eARDS
SA256138C_Serum_71eARDS
SA256139C_Serum_74eARDS
SA256140C_Serum_73eARDS
SA256141C_Serum_72eARDS
SA256142C_Serum_90eARDS
SA256143C_Serum_87eARDS
SA256144C_Serum_66eARDS
SA256145C_Serum_88eARDS
SA256146C_Serum_89eARDS
SA256147B_Serum_57pARDS
SA256148B_Serum_59pARDS
SA256149B_Serum_58pARDS
SA256150B_Serum_55pARDS
SA256151B_Serum_60pARDS
SA256152B_Serum_52pARDS
SA256153B_Serum_56pARDS
SA256154B_Serum_54pARDS
SA256155B_Serum_53pARDS
SA256156B_Serum_47pARDS
SA256157B_Serum_41pARDS
SA256158B_Serum_42pARDS
SA256159B_Serum_43pARDS
SA256160B_Serum_44pARDS
SA256161B_Serum_40pARDS
SA256162B_Serum_39pARDS
SA256163B_Serum_36pARDS
SA256164B_Serum_37pARDS
SA256165B_Serum_38pARDS
SA256166B_Serum_45pARDS
SA256167B_Serum_35pARDS
SA256168B_Serum_50pARDS
SA256169B_Serum_32pARDS
SA256170B_Serum_31pARDS
SA256171B_Serum_49pARDS
SA256172B_Serum_48pARDS
SA256173B_Serum_34pARDS
SA256174B_Serum_33pARDS
SA256175B_Serum_46pARDS
SA256176B_Serum_51pARDS
Showing results 1 to 90 of 90

Collection:

Collection ID:CO002643
Collection Summary:This study was approved by the Asan Institutional Review Board (IRB No. 2019-1017). The inclusion criteria for the cohort were as follows: adult patients aged > 18 years, patients admitted to the medical intensive care unit (ICU) and clinically diagnosed as sepsis according to the Sepsis-2 definition16, and those enrolled within 48 hours of ICU admission. The patients' serum was collected at the time of sepsis cohort enrollment. The healthy control registry included healthy people who visited the Health Screening and Promotion Center at Asan Medical Center. The diagnosis of direct ARDS and indirect ARDS was made through a blind review by the two intensivists reaching the same judgment.Since the eligible ARDS patients belonged to the sepsis cohort, the direct ARDS group included pulmonary ARDS patients with pneumonia-induced sepsis, and the indirect ARDS included extrapulmonary ARDS patients with non-pneumonia induced sepsis.
Sample Type:Blood (serum)
Storage Conditions:-80℃

Treatment:

Treatment ID:TR002662
Treatment Summary:not available

Sample Preparation:

Sampleprep ID:SP002656
Sampleprep Summary:50 μL human serum was mixed well, and 50 μL of internal standard solutions (50 nM C17 ceramide for sphingolipid; 200 nM 18:0 D70 PC and 1 μM 16:0 D31-18:1 PE for plasmalogen and PC/PE profiling) were added. Metabolites were extracted from aqueous and organic phases by liquid-liquid extraction after the addition of chloroform and H2O. Nonpolar metabolites containing lipids were collected from the lower organic phase. The organic phases were dried under vacuum and stored at -20℃oC until further analysis. The dried matter was reconstituted with 50 μL of MeOH prior to LC-MS/MS analysis.

Combined analysis:

Analysis ID AN004198 AN004199
Analysis type MS MS
Chromatography type Reversed phase Reversed phase
Chromatography system Agilent 1290 Agilent 1290
Column Agilent ZORBAX Eclipse Plus C18 (50 x 2.1mm,1.8um) Agilent Pursuit 5 C18 (150 x 2.1mm,5um)
MS Type ESI ESI
MS instrument type QTRAP QTRAP
MS instrument name ABI Sciex 5500 QTrap ABI Sciex 5500 QTrap
Ion Mode POSITIVE POSITIVE
Units nM nM

Chromatography:

Chromatography ID:CH003111
Chromatography Summary:LC-MS/MS (MRM) for phospholipid
Instrument Name:Agilent 1290
Column Name:Agilent ZORBAX Eclipse Plus C18 (50 x 2.1mm,1.8um)
Column Temperature:30
Flow Gradient:isocratic condition of 60% B
Flow Rate:400 µL/min
Solvent A:10 mM ammonium acetate in MeOH/isopropanol/H2O(900/50/50)
Solvent B:10 mM ammonium acetate in MeOH/isopropanol/H2O(940/50/10)
Chromatography Type:Reversed phase
  
Chromatography ID:CH003112
Chromatography Summary:LC-MS/MS (MRM) for sphingolipid
Instrument Name:Agilent 1290
Column Name:Agilent Pursuit 5 C18 (150 x 2.1mm,5um)
Column Temperature:30
Flow Gradient:50% A for 0 min, 50% A for 5 min, 50 to 30% A for 3 min, 30% A for 7 min, 30 to 10% A for 7 min, 10% A for 3 min, 10 to 50% A for 0.1 min, and 50% A for 4.9 min
Flow Rate:200 µL/min
Solvent A:5 mM ammonium formate/MeOH/tetrahydrofuran(500/200/300)
Solvent B:5 mM ammonium formate/MeOH/tetrahydrofuran(100/200/700)
Chromatography Type:Reversed phase

MS:

MS ID:MS003945
Analysis ID:AN004198
Instrument Name:ABI Sciex 5500 QTrap
Instrument Type:QTRAP
MS Type:ESI
MS Comments:Data analysis was performed using Analyst 1.5.2 software. Extracted ion chromatograms (EIC) corresponding to each metabolite were used for quantitation (MRM). The area under the curve of each EIC was normalized to that of the internal standard. For metabolites related to PC/PE profiling, the peak area ratio of each metabolite to that of the internal standard was used for a relative comparison. For plasmalogens, the calibration range was generally 0.1 nM to 10 μM with R2>0.99
Ion Mode:POSITIVE
  
MS ID:MS003946
Analysis ID:AN004199
Instrument Name:ABI Sciex 5500 QTrap
Instrument Type:QTRAP
MS Type:ESI
MS Comments:Data analysis was performed using Analyst 1.5.2 software. Extracted ion chromatograms (EIC) corresponding to each metabolite were used for quantitation (MRM). The area under the curve of each EIC was normalized to that of the internal standard. For ceramides and sphingomyelins, the calibration range was generally 0.1 nM to 10 μM with R2>0.99
Ion Mode:POSITIVE
  logo